← Eichor
Condition: Resectable Pancreatic Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Resectable Pancreatic Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Ashish Manne · NCT05624918Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
Phase 2 · 1 location(s) · Hamilton Health Sciences Corporation · NCT04452461Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
NA · 1 location(s) · Minia University · NCT07022015A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Phase 3 · 1 location(s) · Minia University · NCT07081360Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Phase 2 · 1 location(s) · Loma Linda University · NCT03492671Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal
Phase 2 · 1 location(s) · Mayo Clinic · NCT05518903Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · West Virginia University · NCT04911816Adjuvant Pancreatic Therapy Guided by MRD
NA · 1 location(s) · Ruijin Hospital · NCT06966440Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05462496Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Phase 2 · 10 location(s) · Erasme University Hospital · NCT05083247Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreat
Phase 1/Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06782932NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06821997AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase N/A · 2 location(s) · Roswell Park Cancer Institute · NCT06320717Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 · 2 location(s) · Washington University School of Medicine · NCT06141031CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · 4 location(s) · Proton Collaborative Group · NCT02598349HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Phase 2 · 2 location(s) · Zhejiang University · NCT07240766PULSAR in Systemic Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07269626Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05688215A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05851924Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Phase 1/Phase 2 · 1 location(s) · University Hospital, Lille · NCT05116072
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.